All In Biotech

Drug Trial Radar · NCT04872101

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

473

Actual

Start

May 25, 2021

Primary completion

Dec 27, 2022

Study completion Jan 6, 2023

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
May 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

Conditions

  • Chronic Hand Eczema

Interventions

  • Delgocitinib creamDrug

    Cream for topical application

  • Cream vehicleDrug

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With IGA-CHE TS at Week 16Time frame: 16 weeks

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • LEO Investigational Site

    Brussels, Belgium

  • LEO Investigational Site

    Edegem, Belgium

  • LEO Investigational Site

    Ghent, Belgium

  • LEO Investigational Site

    Kortrijk, Belgium

  • LEO Investigational Site

    Leuven, Belgium

  • LEO Investigational Site

    Loverval, Belgium

  • LEO Investigational Site

    Maldegem, Belgium

  • LEO Investigational Site

    Surrey, British Columbia, Canada

  • LEO Investigational Site

    Vancouver, British Columbia, Canada

  • LEO Investigational Site

    Fredericton, New Brunswick, Canada

  • LEO Investigational Site

    Ajax, Ontario, Canada

  • LEO Investigational Site

    Cobourg, Ontario, Canada

  • LEO Investigational Site

    Etobicoke, Ontario, Canada

  • LEO Investigational Site

    Hamilton, Ontario, Canada

  • LEO Investigational Site

    Toronto, Ontario, Canada

  • LEO Investigational Site

    Waterloo, Ontario, Canada

  • LEO Investigational Site

    Windsor, Ontario, Canada

  • LEO Investigational Site

    Aarhus, Denmark

  • LEO Investigational Site

    Copenhagen, Denmark

  • LEO Investigational Site

    Hellerup, Denmark

  • LEO Investigational Site

    Aachen, Germany

  • LEO Investigational Site

    Bad Bentheim, Germany

  • LEO Investigational Site

    Frankfurt, Germany

  • LEO Investigational Site

    Friedrichshafen, Germany

  • LEO Invesitgational Site

    Hanover, Germany

  • LEO Investigational Site

    Jena, Germany

  • LEO Investigational Site

    Lübeck, Germany

  • LEO Investigational Site

    Mahlow, Germany

  • LEO Investigational Site

    Münster, Germany

  • LEO Investigational Site

    Stuttgart, Germany

  • LEO Investigational Site

    Amsterdam, Netherlands

  • LEO Investigational Site

    Bergen op Zoom, Netherlands

  • LEO Investigational Site

    Breda, Netherlands

  • LEO Investigational Site

    Groningen, Netherlands

  • LEO Investigational Site

    Hoofddorp, Netherlands

  • LEO Investigational Site

    Utrecht, Netherlands

  • LEO Investigational Site

    Bialystok, Poland

  • LEO Investigational Site

    Lublin, Poland

  • LEO Investigational Site

    Rzeszów, Poland

  • LEO Investigational Site

    Warsaw, Poland

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.